CeGaT Standalone TMB Analysis

CeGaT is now offering the analysis of tumor mutational burden (TMB) as a standalone diagnostic. CeGaT's TMB analysis has been available since 2017, as a part of its Somatic Tumor Panel for Treatment Decisions. Offered as a stand-alone analysis, the TMB diagnostic is now available with shorter turnaround times, improved cost-efficiency, and features CeGaT's high quality.